Scientific Advisory Board
| NAME | POSITION |
|---|---|
| C. Budd Colby, Ph.D. | Chair of the Scientific Advisory Board |
| Michael H. Cynamon, M.D. | Scientific Advisor, Drug Discovery |
| Michael P. Doyle, Ph.D. | Scientific Advisor, Drug Discovery |
| Michael Dudley, PharmD | Scientific Advisor, Drug Discovery |
| John Lonsdale, Ph.D. | Scientific Advisor, Drug Discovery |
| Brian Geisbrecht, Ph.D. | Scientific Advisor, Diagnostics |
| Candace McCombs, Ph.D. | Scientific Advisor, Diagnostics |
| Reiko Nakamura, Ph.D. | Scientific Advisor, Diagnostics |
| Emil Skamene, M.D. | Scientific Advisor, Diagnostics |
C. Budd Colby, Ph.D.
SAB Chair
Dr. Colby has twelve years of academic research and twenty-four years in the biotechnology industry. From 1967 to 1979, Dr. Colby held research and teaching positions at several prestigious academic institutions and carried out research in the areas of cancer and infectious diseases. In 1979, Dr. Colby initiated and then managed the recombinant interferon program at Cetus Corp. In 1983, he joined Triton Biosciences, Inc. as the founding scientist and was the lead technical person on the senior management team responsible for developing human recombinant interferon-beta (Betaseronâ) for multiple sclerosis and Fludaraâ for chronic lymphocytic leukemia. Following the sale of Triton Biosciences, he served as VP, R&D at Metabolex, Inc., a biotechnology company focused on diabetes (1992-1995) and was later VP, Business Development and COO of Neugenesis Corporation (1998-2001). From 2000-2002, Dr. Colby was a Senior Industry Advisor and Special Partner with TVM Techno Venture Partners, an international venture capital firm with offices in Munich, Boston and San Francisco.